CONCLUSION
These prototypes demonstrated the feasibility of this automated approach. The automated equipment and the associated disposable
sets or components provides a platform technology to enable commercial manufacturing of complex autologous DC immunotherapies.
Tamara T. Monesmith is a director of manufacturing and process development at Argos Therapeutics, 4233 Technology Dr., Durham, NC 27704, tel.
919.287.6300, fax 919.287.6301, tmonesmith@argostherapeutics.com
.
REFERENCES
1. J. Harris et al., Biochim. Biophys. Acta
1724 (1-2), 127–136 (2005).
2. I. Tcherepanova et al., PLoS One
1 (e1489), 1–10 (2008).
3. S.R. Bennett et al., Nature
393 (6684), 478–480 (1998).
4. J.P. Ridge, R.F. Di, and P. Matzinger, Nature
393 (6684), 474–478 (1998).
5. S.P. Schoenberger et al., Nature
393 (6684), 480–483 (1998).
6. P.T. Coates et al., Expert Rev. Mol. Med.
4 (3),1–21 (2002).
7. M.A. DeBenedette et al., J. Immunother.
34 (1), 45–57 (2011).
8. I.Y. Tcherepanova et al., BMC Mol. Biol.
9 (90), 1–13 (2008).
9. D.M. Calderhead et al., J. Immunother.
31 (8), 731-741 (2008).
10. M.A. DeBenedette et al., J. Immunol.
181 (8), 5296–5305 (2008).
11. A. Jemal et al., CA Cancer J. Clin.
60 (5), 277–300 (2010).
12. S.A. Karumanchi, J. Merchan, and V.P. Sukhatme, Curr. Opin. Nephrol. Hypertens.
11 (1), 37–42 (2002).
13. National Cancer Institute, SEER Cancer Statistics Review, 1975–2007, S.F. Altekruse et al., Eds. (NCI, Bethesda, MD, 2010).
14. K.J. Pienta and D.C. Smith, CA Cancer J. Clin.
55 (5), 300–318 (2005).
|
